NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued on Friday. The brokerage set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Down 4.3 %

NBY stock opened at $0.72 on Friday. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $12.84. The company has a market cap of $3.52 million, a price-to-earnings ratio of -0.01 and a beta of 0.75. The business has a fifty day simple moving average of $0.59 and a 200-day simple moving average of $1.77.

NovaBay Pharmaceuticals (NYSE:NBY) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($1.37) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative net margin of 91.86% and a negative return on equity of 744.33%. The business had revenue of $2.40 million for the quarter. As a group, analysts expect that NovaBay Pharmaceuticals will post -1.41 earnings per share for the current fiscal year.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.